Attend the FierceBiotech 3rd Drug Development Forum!
The leading executive-level forum for biotech strategy & networking | Oct 1-3 | Boston
FibroGen’s partner Astellas has reported phase 3 data that could support filings of their HIF inhibitor in Europe as an oral alternative to EPO.
Corbus bought over 600 compounds from Jenrin Discovery to fuel 1 to 2 new clinical programs in inflammatory and fibrotic diseases annually from 2020.
The first-in-human clinical trial suggested that AST-008 is safe, tolerable and boosts cytokine levels.
Three cancer charities will pour over $39 million into six U.K. and European research projects, to provide for a post-Brexit collaboration model.
Galera will use the proceeds to start a phase 3 study of GC4419, which seems to prevent severe oral mucositis in patients with head and neck cancers.
Tony Polverino joins Zymeworks as chief scientific officer, a role he held on an interim basis at Gilead unit Kite Pharma.
Mahaffy, who remained CEO despite the scandal, is paying $250,000 to get out from under claims he played a prominent role.
Chris Corsico left the CMO spot at Boehringer Ingelheim to fill a new role at GlaxoSmithKline: senior vice president of development.
The app equips physicians to identify suitable clinical trials based on the age, gender, biomarkers and tumors of their patients.
Viking Therapeutics’ lead lipid disorder asset met its endpoints in a midstage trial, dropping cholesterol and liver fat levels in patients with NAFLD.